Business Context and Reporting Period
This Form 6-K filing by NeuroSense Therapeutics Ltd. covers the month of September 2023. The Company is a foreign private issuer headquartered in Herzliya, Israel, with its ordinary shares listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance.
Material Changes
On September 25, 2023, the Company received a notice from Nasdaq stating that its ordinary shares no longer meet the minimum bid price requirement under Listing Rule 5550(a)(2). The closing bid price fell below $1.00 per share for 30 consecutive business days. This notification has no immediate effect on the listing status.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted a 180-calendar day grace period, ending March 25, 2024, to regain compliance.
- Requirements: To comply, the closing bid price must meet or exceed $1.00 per share for at least ten consecutive business days during the grace period.
- Contingencies: If compliance is not achieved by March 25, 2024, the Company may be eligible for an additional 180-day period if it meets other listing standards and intends to cure the deficiency, potentially via a reverse stock split.
- Risks: There is no assurance the Company will regain compliance. Failure to do so may result in delisting.
- Management Action: Management intends to monitor the share price and consider available options if the price remains below $1.00 for an extended period.
Investor Verification Checklist
- Verify the current closing bid price of NeuroSense Therapeutics ordinary shares relative to the $1.00 threshold.
- Monitor the Company's progress toward achieving ten consecutive days of compliance before the March 25, 2024 deadline.
- Watch for announcements regarding a potential reverse stock split if the grace period expires without compliance.
- Review subsequent filings for any updates on delisting risks or alternative compliance strategies.